These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
66. Subclasses of cyclic AMP-specific phosphodiesterase in left ventricular muscle and their involvement in regulating myocardial contractility. Weishaar RE; Kobylarz-Singer DC; Steffen RP; Kaplan HR Circ Res; 1987 Oct; 61(4):539-47. PubMed ID: 2820608 [TBL] [Abstract][Full Text] [Related]
67. Phosphodiesterase inhibition and Ca2+ sensitization. Ravens U; Himmel HM; Flüss M; Davia K; Harding SE Mol Cell Biochem; 1996 Apr 12-26; 157(1-2):245-9. PubMed ID: 8739254 [TBL] [Abstract][Full Text] [Related]
68. Determination of saterinone enantiomers in plasma samples with an internal standard using a Chiralcel OD column, fractionation and reversed-phase chromatography. Rudolph M; Volk D; Schmiedel G J Chromatogr; 1990 Dec; 535(1-2):263-9. PubMed ID: 2089055 [TBL] [Abstract][Full Text] [Related]
69. Imidazo[1,2-a]pyridines. I. Synthesis and inotropic activity of new 5-imidazo[1,2-a]pyridinyl-2(1H)-pyridinone derivatives. Yamanaka M; Miyake K; Suda S; Ohhara H; Ogawa T Chem Pharm Bull (Tokyo); 1991 Jun; 39(6):1556-67. PubMed ID: 1934178 [TBL] [Abstract][Full Text] [Related]
70. Lack of functional influence by prenalterol through alpha 1-adrenoceptors in rat myocardium. Aass H; Hedberg A; Skomedal T; Carlsson E; Osnes JB Acta Pharmacol Toxicol (Copenh); 1983 Jul; 53(1):12-5. PubMed ID: 6310957 [TBL] [Abstract][Full Text] [Related]
71. (Imidazolylphenyl)pyrrol-2-one inhibitors of cardiac cAMP phosphodiesterase. Lampe JW; Chou YL; Hanna RG; Di Meo SV; Erhardt PW; Hagedorn AA; Ingebretsen WR; Cantor E J Med Chem; 1993 Apr; 36(8):1041-7. PubMed ID: 8386770 [TBL] [Abstract][Full Text] [Related]
72. The effects of the stereoisomers of propafenone and diprafenone in guinea-pig heart. Groschner K; Lindner W; Schnedl H; Kukovetz WR Br J Pharmacol; 1991 Mar; 102(3):669-74. PubMed ID: 1364837 [TBL] [Abstract][Full Text] [Related]
73. Synthesis and pharmacological characterization of functionalized 2-pyridones structurally related to the cardiotonic agent milrinone. Fossa P; Menozzi G; Dorigo P; Floreani M; Mosti L Bioorg Med Chem; 2003 Nov; 11(22):4749-59. PubMed ID: 14556790 [TBL] [Abstract][Full Text] [Related]
74. Calcium sensitization as a positive inotropic mechanism in diseased rat and human heart. Nankervis R; Lues I; Brown L J Cardiovasc Pharmacol; 1994 Oct; 24(4):612-7. PubMed ID: 7528844 [TBL] [Abstract][Full Text] [Related]
75. Differential effects of BDF 9148 and DPI 201-106 on action potential and contractility in rat and guinea pig myocardium. Hoey A; Amos GJ; Wettwer E; Ravens U J Cardiovasc Pharmacol; 1994 Jun; 23(6):907-15. PubMed ID: 7523782 [TBL] [Abstract][Full Text] [Related]
76. Phosphodiesterase inhibition by new cardiotonic agents: mechanism of action and possible clinical relevance in the therapy of congestive heart failure. von der Leyen H Klin Wochenschr; 1989 Jun; 67(12):605-15. PubMed ID: 2671473 [TBL] [Abstract][Full Text] [Related]
77. Cardiovascular actions of DPI 201-106, a novel cardiotonic agent. Salzmann R; Scholtysik G; Clark B; Berthold R J Cardiovasc Pharmacol; 1986; 8(5):1035-43. PubMed ID: 2429077 [TBL] [Abstract][Full Text] [Related]
78. Synthesis and biological activity of 4-(diphenylmethyl)-alpha-[(4-quinolinyloxy)methyl]-1-piperazineethanol and related compounds. Sircar I; Haleen SJ; Burke SE; Barth H J Med Chem; 1992 Nov; 35(23):4442-9. PubMed ID: 1447743 [TBL] [Abstract][Full Text] [Related]
79. A method to assess concomitant cardiac phosphodiesterase inhibition and positive inotropy. Kenakin TP; Scott DL J Cardiovasc Pharmacol; 1987 Dec; 10(6):658-66. PubMed ID: 2450236 [TBL] [Abstract][Full Text] [Related]
80. Interaction of enantiomers of hydroxy tolazoline with adrenoceptors. Sengupta JN; Hamada A; Miller DD; Patil PN Naunyn Schmiedebergs Arch Pharmacol; 1987 Apr; 335(4):391-6. PubMed ID: 3600818 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]